XERS
Xeris Biopharma Holdings, Inc. NASDAQ$6.34
Mkt Cap $1.1B
52w Low $4.26
35.7% of range
52w High $10.08
50d MA $5.94
200d MA $7.06
P/E (TTM)
1794.3x
EV/EBITDA
93.3x
P/B
73.6x
Debt/Equity
2.8x
ROE
4.0%
P/FCF
45.1x
RSI (14)
—
ATR (14)
—
Beta
0.99
50d MA
$5.94
200d MA
$7.06
Avg Volume
1.8M
About
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | AMC | 0.03 | 0.06 | +100.0% | 6.02 | -3.5% | -1.3% | +0.8% | +0.3% | -3.5% | -7.0% | — |
| Nov 6, 2025 | AMC | 0.01 | 0.00 | -65.0% | 7.71 | -2.3% | -3.6% | +0.1% | -3.5% | -1.6% | -5.8% | — |
| Aug 7, 2025 | AMC | -0.03 | -0.01 | +66.7% | 6.60 | +0.8% | +3.6% | +9.1% | +10.6% | +10.3% | +10.6% | — |
| May 8, 2025 | AMC | -0.07 | -0.06 | +14.3% | 5.16 | +0.6% | -2.9% | -4.1% | -5.0% | -10.1% | -7.2% | — |
| Mar 6, 2025 | AMC | -0.08 | -0.03 | +62.5% | 4.13 | -0.2% | +2.7% | +11.1% | +6.3% | +10.7% | +10.4% | — |
| Nov 8, 2024 | AMC | -0.09 | -0.06 | +33.3% | 3.47 | -1.2% | -5.5% | -9.2% | -9.2% | -12.1% | -15.9% | — |
| Aug 8, 2024 | AMC | -0.11 | -0.10 | +9.1% | 2.23 | +0.9% | +4.0% | +0.9% | +13.9% | +14.3% | +17.5% | — |
| May 9, 2024 | AMC | -0.12 | -0.14 | -16.7% | 1.88 | +1.6% | -6.4% | +0.5% | +1.1% | +5.3% | +7.4% | — |
| Mar 6, 2024 | AMC | -0.09 | -0.10 | -11.1% | 2.48 | +2.0% | -1.6% | -5.2% | -9.3% | -10.9% | -12.1% | — |
| Nov 9, 2023 | AMC | -0.12 | -0.09 | +25.0% | 1.80 | +3.6% | -6.6% | -10.2% | -13.6% | -18.6% | -13.0% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.12 | $7.08 | +15.7% | -1.6% | -2.9% | -0.8% | -1.3% | -5.1% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.13 | $8.24 | +1.4% | -2.5% | -3.2% | -5.2% | -6.8% | -8.9% |
| Nov 7 | Piper Sandler | Maintains | Neutral → Neutral | — | $7.71 | $7.53 | -2.3% | -3.6% | +0.1% | -3.5% | -1.6% | -5.8% |
| Nov 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.71 | $7.53 | -2.3% | -3.6% | +0.1% | -3.5% | -1.6% | -5.8% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.71 | $7.53 | -2.3% | -3.6% | +0.1% | -3.5% | -1.6% | -5.8% |
| Oct 29 | Oppenheimer | Maintains | Outperform → Outperform | — | $9.23 | $9.44 | +2.3% | +4.2% | +5.2% | +5.1% | +7.3% | +7.3% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.47 | $7.52 | +0.7% | +2.7% | +11.1% | +3.3% | +5.2% | +5.9% |
| Aug 19 | Leerink Partners | Maintains | Outperform → Outperform | — | $7.36 | $7.36 | +0.0% | +0.0% | +2.9% | +3.1% | +5.3% | +5.6% |
| Aug 8 | Craig-Hallum | Maintains | Buy → Buy | — | $6.60 | $6.65 | +0.8% | +3.6% | +9.1% | +10.6% | +10.3% | +10.6% |
| Aug 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.60 | $6.65 | +0.8% | +3.6% | +9.1% | +10.6% | +10.3% | +10.6% |
Recent Filings
8-K · 5.02
!!! Very High
Xeris Biopharma Holdings, Inc. -- 8-K 5.02: Executive Change
Xeris Biopharma director Jeffrey Sherman's departure reduces board oversight capacity and may signal internal governance changes or strategic disagreements among leadership.
Apr 21
8-K
Xeris Biopharma Holdings, Inc. -- 8-K Filing
Xeris Biopharma achieved record 2025 revenues of $292 million and projects 28-33% growth to $375-390 million in 2026, signaling strong commercial execution and investor confidence in its product portfolio.
Mar 2
8-K · 7.01
! Medium
Xeris Biopharma Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
Xeris Biopharma filed a Hatch-Waxman patent infringement lawsuit against two ANDA filers in New Jersey federal court, seeking to block generic competition and extend market exclusivity for its products.
Feb 27
Data updated apr 27, 2026 10:29am
· Source: massive.com